Medsir
Clinical trials sponsored by Medsir, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for breast cancer patients with brain tumors: targeted drug shows promise Results expected Nov 2026 (estimated)
- New radioactive 'Theranostic' drugs aim to find and treat brain tumors Results expected Nov 2026 (estimated)
- New drug shows promise for Hard-to-Treat breast cancer subtype Results expected Jan 2027 (estimated)
- New combo therapy shows promise for Hard-to-Treat breast cancer Results expected Feb 2027 (estimated)
- Could a Chemo-Free cocktail beat early breast cancer? Results expected Mar 2027 (estimated)
-
Promising drug targets lung cancer brain tumors in early trial
Disease control Recruiting nowThis study tests a drug called repotrectinib in 20 people with a specific type of lung cancer (ROS1-positive NSCLC) that has spread to the brain. The main goal is to see if the drug can shrink or eliminate brain tumors. Participants will take the drug by mouth, and doctors will m…
Phase 2 • Sponsor: MedSIR • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo takes aim at rare sarcoma
Disease control Recruiting nowThis study tests a new drug called bexmarilimab (an antibody) combined with the chemotherapy doxorubicin in people with metastatic soft-tissue sarcoma. The trial has two parts: first, finding the safest dose, then checking if the combination helps slow the cancer. About 278 adult…
Phase 1/2 • Sponsor: MedSIR • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Promising combo aims to stall advanced breast cancer
Disease control Recruiting nowThis study tests whether adding everolimus to elacestrant can help people with a certain type of advanced breast cancer (ER+/HER2- with an ESR1 mutation) live longer without their cancer getting worse. About 240 adults whose cancer has stopped responding to standard hormone thera…
Phase 3 • Sponsor: MedSIR • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Blood test may spot breast cancer return before symptoms appear
Disease control Recruiting nowThis study tests whether a blood test that looks for cancer DNA (ctDNA) can find breast cancer returning earlier than usual scans or exams. About 976 people with HR-positive/HER2-negative early breast cancer who had surgery will give blood samples over time. If the test shows sig…
Phase 2 • Sponsor: MedSIR • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New drug shows promise for Hard-to-Treat breast cancer subtype
Disease control Recruiting nowThis study tests a drug called trastuzumab deruxtecan (T-DXd) against the usual treatment (a CDK4/6 inhibitor plus hormone therapy) for people with a certain type of advanced breast cancer. The cancer must be hormone receptor-positive, HER2-low or ultralow, and have a specific ge…
Phase 2 • Sponsor: MedSIR • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New drug duo aims to slow advanced breast cancer
Disease control Recruiting nowThis study tests two drugs, camizestrant and ribociclib, together in people with advanced hormone receptor-positive (HR+) breast cancer. The goal is to see if the combination can delay cancer growth better than current treatments. About 150 adults who have already received hormon…
Phase 2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Ovarian cancer: can a second round of niraparib after surgery keep tumors at bay?
Disease control Recruiting nowThis phase 2 trial is testing whether giving the drug niraparib again after surgery can help women with ovarian cancer whose disease has come back in just a few spots. About 30 participants will take niraparib pills daily until their cancer grows or side effects become too much. …
Phase 2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC